In a recent study, researchers sought to investigate the clinical impact of 1-year certolizumab pegol therapy added to the first year of a 2-year treatment with methotrexate in patients with early rheumatoid arthritis.
In a recent study, funded by Astellas and UCB and published in Annals of the Rheumatic Diseases, researchers sought to investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of a 2-year treatment with methotrexate (MTX) in patients with early rheumatoid arthritis (RA), and to compare that outcome with the clinical impact of a 2-year treatment with MTX alone.
The multicenter, randomized, controlled study investigated patients who had early RA with a poor prognosis and were naïve to MTX treatment. During the first 52 weeks, patients were randomized into 2 arms: the first arm received MTX and CZP (n = 159) and the second arm received MTX and placebo (n = 157). Following this double-blind period, both groups entered a 52-week period of treatment with MTX alone, though patients in need of rescue treatment received open-label CZP.
The researchers observed that remission rates decreased after CZP was discontinued; however, higher rates of remission were maintained through week 104 in the group receiving MTX and CZP (41.5%) versus the group that received MTX and the placebo (29.3%). Patients who were treated with CZP as a rescue therapy showed rapid clinical improvement. The incidence of adverse effects was similar between the 2 treatment arms.
Based on the trial results, the researchers concluded that, in patients with early RA who were naïve to MTX treatment and who had poor prognostic factors, an initial 1 year of CZP added to a 2-year MTX therapy rendered a clinical benefit over 2 years, even after CZP was discontinued.
The study’s authors state that aggressive initial treatment with a biological disease-modifying anti-rheumatic drug such as CZP is a potential treatment option at the early stage of RA, especially for patients who have poor prognoses. After patients achieve treatment goals, such biologics may be withdrawn. While such an aggressive approach may not be appropriate for all patients, the authors caution, those at high risk for rapid joint destruction may benefit from such a protocol. The approach, the authors say, has the potential to prevent irreversible joint damage, reduce the risk of adverse events, and provide a more cost-effective treatment for RA in the long term.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Survey Finds Korean Oncologists Trust Biosimilars But Prescribe Originators More
May 13th 2024A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, they often prescribe the originators due to factors like lack of patient trust in biosimilars and lower than expected cost savings.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.